DXCM vs. MDLN: DexCom vs. Medline Stock Comparison

Company Profile

DexCom (DXCM) and Medline (MDLN) both belong to the Health Care Equipment & Supplies industry, though DXCM is classified under Health Care Equipment while MDLN falls under Health Care Supplies.

DexCom (DXCM) has been public since April 14, 2005, giving it decades of market history across multiple cycles, while Medline (MDLN) listed only on December 17, 2025 and lacks comparable through-cycle data.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Medline (MDLN) reports a negative beta of -0.93, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. DexCom (DXCM) has a non-negative beta of 1.43.

Risk-Adjusted Performance

Risk-Return Positioning

Both DXCM and MDLN need 1-year volatility and 1-year return to plot risk-return positioning.

Risk-Adjusted Metrics

Profitability

DexCom (DXCM) at 37.67% sits in the top ROE quartile, while Medline (MDLN) at 4.85% is closer to the peer norm — stronger capital efficiency for DXCM.

DexCom (DXCM) at 19.42% retains a top-quartile share of revenue as profit, ahead of Medline (MDLN) at 1.85%, which keeps about the industry-typical share.

DexCom (DXCM) at 24.34% operates in the top operating margin quartile, ahead of Medline (MDLN) at 5.22%, which runs around its industry’s norm.

Profitability Metrics

Growth

Only one side can be read here: DexCom (DXCM) reports revenue growth of 15.60%, ranked against its industry; Medline (MDLN) has no revenue growth figure this period.

Both companies show strong earnings momentum, but Medline (MDLN) at 117.38% is the standout with EPS growth above its industry range; DexCom (DXCM) at 47.18% also sits in the top quartile.

Growth Metrics

Financial Strength

DexCom (DXCM) at 1.74 keeps current ratio within its industry’s typical mid-range, while Medline (MDLN) at 4.04 sits above its industry’s typical mid-range — comfortable liquidity, though possibly with more idle current assets relative to peers.

Both DexCom (DXCM) at 0.55 and Medline (MDLN) at 0.65 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Neither DexCom (DXCM) nor Medline (MDLN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither DexCom (DXCM) nor Medline (MDLN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

DexCom (DXCM) at 31.26 is near its industry’s usual P/E ratio, while Medline (MDLN) at 90.09 sits above its peer range — an unusually expensive price for MDLN’s trailing earnings.

Medline (MDLN) at 1.70 is priced about in line with its industry on P/S ratio, while DexCom (DXCM) at 5.80 sits in the pricier quartile — DXCM costs more per dollar of sales.

Medline (MDLN) at 2.95 is valued about in line with its industry on P/B ratio, while DexCom (DXCM) at 11.68 carries an above-peer premium to book — DXCM is pricier on assets.

Valuation Metrics